The prognostic value of excision repair cross-complementing Group 1 expression in nasopharyngeal cancer patients

Imjai Chitapanarux; Suree Lekawanvijit; Patumrat Sripan; Pongsak Mahanupab; Somvilai Chakrabandhu; Wimrak Onchan; Pichit Sittitrai; Donyarat Boonlert; Hanpon Klibngern; Wisarut Samuckkeethum

doi:10.4103/jrms.JRMS_787_18

Users Online: 201

ORIGINAL ARTICLE

Year : 2020 | Volume : 25 | Issue : 1 | Page : 34

The prognostic value of excision repair cross-complementing Group 1 expression in nasopharyngeal cancer patients

Imjai Chitapanarux¹, Suree Lekawanvijit², Patumrat Sripan³, Pongsak Mahanupab², Somvilai Chakrabandhu⁴, Wimrak Onchan⁴, Pichit Sittitrai⁵, Donyarat Boonlert⁵, Hanpon Klibngern⁵, Wisarut Samuckkeethum⁵
¹ Division of Radiation Oncology, Department of Radiology; Northern Thai Research Group of Radiation Oncology (NTRG-RO); Chiang Mai Cancer Registry, Maharaj Nakorn Chiang Mai Hospital, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand
² Department of Pathology, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand
³ Northern Thai Research Group of Radiation Oncology (NTRG-RO); Chiang Mai Cancer Registry, Maharaj Nakorn Chiang Mai Hospital, Faculty of Medicine; Research Institute for Health Sciences, Chiang Mai University, Chiang Mai, Thailand
⁴ Division of Radiation Oncology, Department of Radiology; Northern Thai Research Group of Radiation Oncology (NTRG-RO), Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand
⁵ Department of Otolaryngology, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand

Correspondence Address:
Prof. Imjai Chitapanarux
Division of Radiation Oncology, Department of Radiology, Faculty of Medicine, Chiang Mai University, 110 Intawarorose Road, Chiang Mai 50200
Thailand

Source of Support: None, Conflict of Interest: None

Check

DOI: 10.4103/jrms.JRMS_787_18

Background: Overexpression of excision repair cross-complementing Group 1 (ERCC-1) is related to cisplatin resistance and defective repair of radiation damage. The purpose of this study was to evaluate the clinical significance of excision (ERCC-1) expression in nasopharyngeal cancer (NPC). Materials and Methods: We conducted a retrospective review of patients diagnosed with NPC between 2000 and 2013. The archived tissues were analyzed using immunohistochemistry to determine ERCC-1 expression. The ERCC-1 expression level along with other clinical factors and overall survival (OS) were analyzed. Hazard ratio (HR) with a 95% confidence interval was calculated to assess the risk. Results: The analysis of ERCC-1 expression was available in 262 NPC patients who had medical records at our hospital. Among those patients, 221 (84%) were treated with curative radiotherapy (RT)/concurrent chemoradiotherapy, 22 (7%) were treated with palliative RT alone, and 19 (9%) were given best supportive care. There was no correlation between ERCC-1 expression and stage of cancer or OS. No difference in 5-year OS was found between patients with low ERCC-1 expression and high ERCC-1 expression (38% vs. 36%; P = 0.981). The adjusted HR (aHR) of cancer death increased with cancer stage (aHR = 2.93 for advanced Stages III–IV; P = 0.001) and age (aHR = 2.11 for age >55; P ≤ 0.001). ERCC-1 expression exhibited no prognostic significance in our study (aHR = 1). Conclusion: In this study, ERCC-1 expression has no statistical significance to be considered a prognostic factor for OS among NPC patients. On the other hand, cancer stage, age, and types of treatment can be prognostic factors in NPC patients.

[FULL TEXT] [PDF]*

Table of Contents

Similar in PUBMED

Search Pubmed for

Search in Google Scholar for

Related articles

Citation Manager

Access Statistics

Reader Comments

Email Alert *

Add to My List *

* Requires registration (Free)

Article Access Statistics

Viewed	675

Printed	40

Emailed	0

PDF Downloaded	88

Comments	[Add]